Rezpegaldesleukin is a recombinant protein commercialized by Eli Lilly and Co, with a leading Phase I program in Atopic Dermatitis (Atopic Eczema). According to Globaldata, it is involved in 14 clinical trials, of which 8 were completed, 5 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Rezpegaldesleukin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Rezpegaldesleukin is expected to reach an annual total of $8 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NKTR-358 is under development for the treatment of immunological disorders including atopic dermatitis and plaque psoriasis. It is a recombinant protein administered through subcutaneous route. It acts by targeting interleukin 2 receptor subunit alpha and gamma.
It was also under development for the treatment of ulcerative colitis and systemic lupus erythematosus (SLE).
Eli Lilly and Co Overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa, and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$28,541.4 million for the fiscal year ended December 2022 (FY2022), an increase of 0.8% over FY2021. In FY2022, the company’s operating margin was 25%, compared to an operating margin of 21% in FY2021. In FY2022, the company recorded a net margin of 21.9%, compared to a net margin of 19.7% in FY2021. The company reported revenues of US$6,960 million for the first quarter ended March 2023, a decrease of 4.7% over the previous quarter.
For a complete picture of Rezpegaldesleukin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.